---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034115"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:10:00.226772+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway

## Summary
- FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.
- Net loss for Q2 2024 was $3.0M ($1.01 per share) vs $2.6M ($1.94 per share) in Q2 2023; per-share reflects 1-for-20 reverse split.
- Cash and cash equivalents $5.6M as of June 30, 2024; R&D expenses unchanged at $1.7M, G&A increased to $1.4M.
- Preclinical NGC-Iri study shows greater SN-38 accumulation in tumor vs non-cancer tissues compared to irinotecan and Onivyde.
- NGC-Cap Phase 1b data: 66.7% of patients had partial response or stable disease; progression-free survival 5-11 months.

## SEC filing metadata
- accession: 0001493152-24-034115
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224034115/0001493152-24-034115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224034115/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034115
- JSON: https://secwatch.observer/filing/0001493152-24-034115.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.